United Cannabis Corporation Enters Licensing Agreement With Vessel Life Science LLC
Agreement Grants Vessel Life Science LLC Exclusive Distribution Rights to Company’s Prana Bio Nutrient Medicinals in the State of Pennsylvania
DENVER, CO / ACCESSWIRE / February 23, 2017 /United Cannabis Corporation (CNAB) (the “Company” or “United Cannabis”) today announced that it has signed an exclusive licensing agreement with Vessel Life Sciences (“VLS”) to produce and distribute its products, including the award-winning Prana Bio Nutrient Medicinals, throughout Pennsylvania.
Established in 2016, Vessel Life Science LLC is dedicated to advancing the use of cannabinoids in medicine, with a focus on the refinement of genetics for medical grade strains of CBD-rich cannabis plants for the commonwealth of Pennsylvania’s patient base. Founded on the principles of patient-driven results, VLS’ mission is to offer the highest quality of products that indisputably prove and reinforce the use of medical marijuana for patient benefits and health advances.
United Cannabis’ Prana line offers a wide selections of raw and active cannabinoid supplements with multiple delivery methods that have accurately dosed medicine from 1mg to 100mg. These products and patient-driven programs are designed to help regulate the body’s endogenous endocannabinoid system, perhaps the most important physiological system in maintaining human health. Prana products are most effective when used in conjunction with the extended services provided by the A.C.T. Now Program.
Collin Palmer, CEO of Vessel Life Science, commented on the agreement, “There is a strong demand for medical cannabis in Pennsylvania, and we are looking to become a leader in this market. Our exclusive partnership with United Cannabis and their Prana Bio Nutrient products will enable us to deliver clean and effective medicine to thousands of patients in need as soon as Act 16 is fully implemented.”
Tony Verzura, United Cannabis’ Chief Technology Officer, went on to say, “Vessel Life Sciences is ideally suited to bring our products to Pennsylvania. Their team has over 30 years’ combined experience across the spectrum of the cannabis industry, including engineered facilities, regulatory compliance, genetics, cultivation, good manufacturing practices, proprietary extraction methods, branding, marketing, and wholesale distribution. Their expertise gives us a distinct competitive advantage as we work to execute a fast and efficient launch of our Prana products and ACT Program throughout the state.”
About United Cannabis Corporation
The Company’s Prana Bio Medicinal products provide patients a simple, safe, accurate, and easy way to mix match cannabinoids for therapeutic purpose. These products are broken into 5 easy to use categories that are available in capsules, sublinguals, and topical delivery methods. The company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis derived terpenes to increase bioavailability. Prana Bio Medicinal products are NON-GMO, ethanol free, alcohol free, glycerin free, gluten free, 100% naturally derived, chemical-free, solventless, and hypoallergenic.
For further information, please visit www.unitedcannabis.us.
About Vessel Life Science:
Vessel Life Science’s Strategic Pennsylvania MMJ Partners have been involved with medical cannabis since it was permissible in California in 1999, turning their focus to Colorado during the infancy stage of legalized medical cannabis in 2009. With the benefit of more than 30 years’ combined experience, Vessel Life’s partners have accumulated an extensive knowledge base across the spectrum of the cannabis industry, including engineered facilities, security, regulatory compliance, genetics, cultivation, good manufacturing practices (GMP), proprietary extraction methods, branding, retail operations (SOP), marketing, and wholesale distribution.
For further information, please visit www.vessellifescience.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE: United Cannabis Corporation